Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | EMA restrict pembrolizumab/atezolizumab usage in urothelial cancer

The European Medicines Agency have announced their recommendation to restrict the use of pembrolizumab and atezolizumab to the first-line treatment of urothelial cancer patients with high PD-L1 expression. Here, Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute, London, UK, explains the reasoning behind this development, and shares his insights on why this is a positive movement towards more personalized treatment for patients. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.